Table 1. Clinicopathological factors of patients by tumor location.
| Location | CC | RC | P value | CC | RC | P value | ||
|---|---|---|---|---|---|---|---|---|
| Factors | (N=3039) Number (%) |
(N=1953) Number (%) |
CC vs RC | Recurrence rate |
P value | Recurrence rate |
P value | CC vs RC |
| Age | ||||||||
| ≤64 | 1041 (34) | 998 (51) | <0.0001 | 15.4% | NS | 19.3% | NS | 0.018 |
| 65–74 | 1090 (36) | 629 (32) | 13.1% | 21.6% | <0.0001 | |||
| 75≤ | 908 (30) | 326 (17) | 13.4% | 18.4% | 0.03 | |||
| Gender | ||||||||
| Male | 1678 (55) | 1192 (61) | <0.0001 | 14.8% | NS | 21.4% | 0.041 | <0.0001 |
| Female | 1361 (45) | 761 (39) | 13.0% | 17.6% | 0.0044 | |||
| Preoperative CEA | ||||||||
| High | 831 (27) | 561 (29) | 0.043 | 23.9% | <0.0001 | 30.5% | <0.0001 | 0.0068 |
| Normal | 2115 (70) | 1310 (67) | 10.3% | 15.3% | <0.0001 | |||
| Unknown | 93 ( 3) | 82 (4) | 9.7% | 20.7% | 0.04 | |||
| Histological Type | ||||||||
| Well/Moderately | 2867 (94) | 1881 (96) | 0.0069 | 13.6% | NS | 19.2% | 0.0002 | <0.0001 |
| Poorly | 74 (2) | 31 (2) | 21.6% | 41.9% | 0.034 | |||
| Mucinous | 98 (3) | 41 (2) | 18.4% | 36.6% | 0.021 | |||
| Tumor depth | ||||||||
| T1 | 592 (19) | 355 (18) | <0.0001 | 1.0% | <0.0001 | 4.8% | <0.0001 | 0.0003 |
| T2 | 447 (15) | 438 (22) | 3.6% | 11.9% | <0.0001 | |||
| T3 | 1411 (46) | 971 (50) | 14.0% | 25.4% | <0.0001 | |||
| T4 | 589 (19) | 189 (10) | 35.0% | 38.6% | NS | |||
| Nodal status | ||||||||
| N0 | 2039 (67) | 1256 (64) | <0.0001 | 7.9% | <0.0001 | 14.1% | <0.0001 | <0.0001 |
| N1 | 786 (26) | 483 (25) | 22.3% | 26.3% | NS | |||
| N2 | 214 (7) | 214 (119) | 41.1% | 39.7% | NS | |||
| Lymphatic invasion | ||||||||
| ly0 | 1323 (44) | 793 (41) | NS | 8.9% | <0.0001 | 13.1% | <0.0001 | 0.0023 |
| ly1 | 1261 (41) | 853 (44) | 14.9% | 21.3% | 0.0001 | |||
| ly2 | 378 (12) | 262 (13) | 23.5% | 32.4% | 0.013 | |||
| ly3 | 58 (2) | 37 (2) | 48.3% | 45.9% | NS | |||
| Unknown | 19 (1) | 8 (0) | 10.5% | 12.5% | NS | |||
| Venous invasion | ||||||||
| v0 | 1193 (39) | 610 (31) | <0.0001 | 6.4% | <0.0001 | 10.5% | <0.0001 | 0.0025 |
| v1 | 1188 (39) | 765 (39) | 15.3% | 19.3% | 0.021 | |||
| v2 | 493 (16) | 436 (22) | 23.5% | 30.0% | 0.025 | |||
| v3 | 140 (5) | 125 (6) | 32.1% | 35.2% | NS | |||
| Unknown | 25 (1) | 17 (1) | 20% | 11.8% | NS | |||
| Stage | ||||||||
| I | 890 (29) | 641 (33) | <0.0001 | 1.2% | <0.0001 | 8.4% | <0.0001 | <0.0001 |
| II | 1149 (38) | 614 (31) | 13.1% | 20.0% | 0.0002 | |||
| III | 1000 (33) | 697 (36) | 26.3% | 30.4% | NS | |||
| Adjuvant therapy | ||||||||
| Stage I | ||||||||
| Yes | 18 (2) | 26 (4) | 0.019 | 5.6% | NS | 7.7% | NS | NS |
| No | 872(98) | 615 (96) | 1.1% | 8.5% | <0.0001 | |||
| Stage II | ||||||||
| Yes | 184 (16) | 126 (20) | 0.019 | 17.9% | 0.036 | 25.4% | NS | NS |
| No | 965 (84) | 489 (80) | 12.2% | 18.6% | 0.001 | |||
| Stage III | ||||||||
| Yes | 643 (64) | 509 (73) | 0.0002 | 25.8% | NS | 31.0% | NS | NS |
| No | 357 (36) | 188 (27) | 27.2% | 28.7% | NS | |||
CEA: Carcinoembryonic antigen, CC: colon cancer, NS: Not significant, Poorly: poorly differentiated adenocarcinoma, Mucinous: mucinous adenocarcinoma.
RC: rectal cancer, Well/Moderately: well differentiated/moderately differentiated adenocarcinoma.